BTI is a German research organization in the field of biopharmaceutics which supports the translation from academic research into commercial use. Within this scope BTI initiates its own research programs and makes the outcome available for partners from the industry. Among these programs BTI developed a versatile enzymatic tool for site-specific generation of ADCs which enables standardized labeling within minutes under full control of conjugation sites and ratios. Other advantages of this TrypCo technology are: 1) an efficient N- and C-terminal modification in biological buffers with no need for co-factors or special agents, 2) homogeneous products, 3) high flexibility towards linker and functionalities and 4) a straightforward upscaling.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):